Center for Human Genetics and Laboratory Diagnostics, Dr. Klein, Dr. Rost and Colleagues

You are here: Pharmacogenetics » Chemotherapy Toxicity (Overview) » Paclitaxel Treatment

Paclitaxel Treatment [T88.7]

OMIM number: 601129 (CYP2C8)

Dipl.-Biol. Birgit Busse

Scientific Background

The enzyme CYP2C8 is majorly involved in the metabolism of the chemotherapeutic agent paclitaxel. Variants in the CYP2C8 gene can result in reduced enzyme activity.

The CYP2C8*3 allele leads to a reduction of enzyme activity up to 15% of the standard. Approximately 13% of all Caucasians are heterozygous, approximately 1.7% homozygous for the CYP2C8*3 allele. In both cases, toxicity may arise under the treatment with paclitaxel. Determining the CYP2C8 genotype prior to treatment provides the opportunity for dosage adaption of paclitaxel to prevent side-effects.